|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on December 5, 2002; DOI 10.1182/blood-2002-06-1634.
HEMATOPOIESIS
From the Centre de Recherches du Service de Santé
des Armées and Centre de Transfusion Sanguine des Armées,
La Tronche and Clamart, France.
Recovery from radiation-induced (RI) myelosuppression depends on
hematopoietic stem and progenitor cell survival and the active proliferation/differentiation process, which requires early cytokine support. Single cytokine or late-acting growth factor therapy has
proved to be inefficient in ensuring reconstitution after severe RI
damage. This work was aimed at evaluating the in vivo survival effect
of combinations of early-acting cytokines whose antiapoptotic
activity has been demonstrated in vitro: stem cell factor (SCF [S]),
FMS-like tyrosine kinase 3 ligand (FLT-3 ligand [F]),
thrombopoietin (TPO [T]), interleukin-3 (IL-3 [3]), and stromal
derived factor-1 (SDF-1). B6D2F1 mice underwent total body irradiation
at 8 Gy cesium Cs 137 The pancytopenia that occurs after irradiation is
mainly the consequence of early death of hematopoietic stem and
progenitor cells (HSPCs), and its severity and duration depend on the
level of bone marrow (BM) cell loss.1 Numerous studies
have shown the efficacy of hematopoietic growth factors (HGFs) in
stimulating neutrophil and platelet recovery in animals and humans
after myeloablation.2 Granulocyte-colony-stimulating
factor (G-CSF), granulocyte macrophage-colony-stimulating factor
(GM-CSF), interleukin-3 (IL-3), IL-11, and thrombopoietin (TPO) are
among the most efficient cytokines.3 These molecules have
primarily been evaluated as monotherapy, but the simultaneous or
sequential administration of 2 complementary cytokines has resulted in
better patterns of hematologic recovery.4-7 As a clinical
application, victims of the criticality nuclear accident in Tokai-mura,
Japan, recently were given G-CSF, megakaryocyte growth and development
factor (MGDF), and erythropoietin in combination.8 In most
preclinical trials, HGF administration starts the day after
myeloablative injury. The duration of treatment covers at least 15 days
until neutrophil or platelet recovery. Prolonged administration
stimulates HSPCs to cycle, proliferate, and differentiate, but it may
also induce adverse effects such as proinflammatory and immunogenic
activity.9 This led us to consider short-term treatment
schedules. Thus far, few cytokines have been tested as early
and acute therapy. IL-1 seemed to be a pivotal hematopoietic cytokine
in the therapy for radiation injury before adverse effects were
established.10 G-CSF injected into mice 2 hours after
irradiation as a single injection has been shown to induce a good level
of protection against 30-day mortality.11 Unfortunately,
this factor was unsuccessful in restoring thrombopoiesis in
myeloablated nonhuman primates. Despite a notable level of platelet
recovery observed in sublethally or lethally irradiated mice, TPO did
not prevent a profound neutropenic nadir after lethal irradiation,
which may be involved in the observed lethality.12
Apoptosis has been shown to play a major role in HSPC death soon after
irradiation in vitro13 and in vivo.14,15 If a subset of highly radioresistant stem cells recapitulates long-term hematopoiesis16,17 (a notion supported by the eventual
autologous reconstitution in accidentally irradiated victims despite
bone marrow allotransplantation), the preservation of residual
cytokine-sensitive HSPCs from radiation-induced (RI) apoptosis would be
critical for myeloablated host survival.15 In particular,
the mitigation of morbidity and mortality caused by the initial
neutropenia and thrombocytopenia requires the preservation and
stimulation of less immature HSPCs. In vitro studies dealing
with RI apoptosis of CD34+ cells have shown that early
management is necessary to maintain cell clonogenicity. In fact,
cytokines active in the early stages of hematopoiesis preserve
CD34+ cells, provided they are added in combination soon
after irradiation.13 Thus far, we found the best
antiapoptotic combination to be stem cell factor (SCF) + FMS-like
tyrosine kinase 3 ligand (FLT-3 ligand) + TPO + IL-3 (4F). In
addition, stromal derived factor-1 (SDF-1) chemokine has been reported
to be an antiapoptotic factor toward HSPC in vitro18,19
and to participate in host defenses against DNA damage.20
All these data prompted us to use cytokine combinations as an early
treatment of RI injury.
The purpose of our study was to assess the capacity of antiapoptotic
cytokines to rescue mice from radiation when cytokines are given as an
early treatment to counteract cell death, especially potentially lethal
lesions, as a combination to ensure multilineage protection, and as a
short-term treatment to avert adverse effects. In this study, we report
the therapeutic benefit for lethally irradiated mice of the
administration at 2 hours and 24 hours after irradiation of multiple
cytokine combinations involving SCF, FLT-3 ligand, TPO, IL-3, and SDF-1
in comparison with TPO or SDF-1 alone. The highest 30-day survival
rates were obtained with 4F and 4F + SDF-1 (5F). Long-term
follow-up revealed delayed death, and treated irradiated mice displayed
a reduced long-term hematopoietic potential compared with normal mice.
However, approximately half the protection provided by the cytokines at
30 days was still evident 300 days after total body irradiation (TBI).
To dissect the mechanism of action of 4F, we used a nonhuman primate
model and showed that 4F administration 2 hours after TBI prevented BM
CD34+ cells from apoptosis and that 4F did not stimulate
CD34+ cells to cycle within the first 24 hours after in
vitro irradiation.
Animals
Mouse model
Nonhuman primate model Adult male cynomolgus monkeys (Macaca fascicularis) weighing 8 kg each were housed at the Centre de Recherches du Service de Santé des Armées (CRSSA)-accredited animal facility in individual cages in holding rooms equipped with a reverse-filtered air barrier (10 air changes per hour, 100% fresh air) and full-spectrum light (8:00 AM to 8:00 PM) and conditioned to 23°C with a relative humidity of 60%. Animals were fed commercial primate chow supplemented with fresh fruit and were provided tap water ad libitum.Irradiation In vitro irradiation.
Cells were irradiated at 2.5 Gy using a cobalt Co 60 Total body irradiation. Mice placed in ventilated polycarbonate canisters underwent TBI with a single 8 Gy dose using a cesium Cs 137 gamma source (dose rate, 10 Gy/min). Dosimetry was performed using an ionization chamber and thermoluminescent aluminum oxide dosimeters. Survival curves previously performed established that 8 Gy constitutes the 90% ± 5% lethal dose at 30 days. Anesthetized monkeys (n = 6) placed in a restraining chair were exposed to global unilateral front irradiation with a 60Co source at a total midline tissue dose of 5 Gy (measured in air at
the anterior iliac crest level) with a dose rate of 20 cGy/min.
Dosimetry was performed using ionizing chambers and thermoluminescent dosimeters.
Cytokines Recombinant murine SCF (S), FLT-3 ligand (F), TPO (T), IL-3 (3), and SDF-1 were used (R&D Systems, Abingdon, United Kingdom) for the
mouse study. Recombinant human (rh) TPO, rhSCF, rhFLT-3 ligand, and
rhIL-3 (R&D Systems) were used for the monkey study.
CD34+ cells Cell collection. For the in vitro study, baboon-mobilized peripheral blood (PB) CD34+ cells were collected using leukapheresis as previously described.22 Cell culture. Within 30 minutes of irradiation or sham irradiation, cells were washed and resuspended (1 × 105 cells/mL) in serum-free medium H00 (RTM-Mabio, Tourcoing, France). Unirradiated and irradiated cells were then incubated with the 4F cytokine combination (FLT-3 ligand + TPO + SCF + IL-3; 50 ng/mL each) in 6-well plates at 37°C in a humidified incubator with 5% CO2 in air. Cells were analyzed after 24 hours and 3 days of incubation relative to fresh control cells. Cell cycle analysis. DNA and nuclear protein Ki67 (only present during the G1 and S/G2/M phases of the cell cycle) cell content were evaluated using flow cytometry.23 Briefly, after CD34+ cell labeling with antihuman CD34, clone 566, monoclonal antibody (mAb) conjugated to phycoerythrin (PE) (BD Biosciences, Le Pont de Claix, France), and cell fixation in phosphate-buffered saline (PBS)-formaldehyde 1%, cells were permeabilized in PBS-Triton 0.1% (30 minutes on ice). After two washes, cells were incubated with anti-Ki-67 MIB-1 mAb conjugated to fluorescein isothiocyanate (FITC; Beckman Coulter, Villepinte, France) for 1 hour at 4°C. Finally cells were washed and resuspended in PBS 7-aminoactinomycin (7 AAD, 0.5µg/mL; Sigma, St Louis, MO). Flow cytometric analysis was performed within 1hour, and G0, G1, S/G2/M cell contents were determined (FCS Express; De novo Software, Toronto, ON, Canada). In vivo apoptosis evaluation. Current methodologies used for evaluating in vitro cell death are inefficient for in vivo evaluation because apoptotic cells are progressively eliminated by phagocytes. It is, therefore, necessary to identify a pertinent early marker. We chose to measure the mitochondrial transmembrane potential (MTP) at the CD34+ cell level by flow cytometry using 3, 3' dihexyloxacarbocianine iodide (DiOC6; Interchim, Montluçon, France).24 MTP is known to be increased during the early phase of apoptosis,25 before the final step of depolarization. Humeral BM was harvested after TBI, and mononuclear cells were isolated by cell density separation and were DiOC6/CD34 double-labeled in 2 steps. First, cells were incubated with 25 nM/L DiOC6 for 15 minutes at 37°C in PBS. Cells were then put on ice to prevent the leak of DiOC6 and were then stained with anti-CD34 mAb for 1 hour. Nucleated cells were selected for analysis using 0.5 µg/mL LDS751 (Interchim) addition. DiOC6 uptake was expressed in terms of mean fluorescence intensity (MFI). For each sample, DiOC6 uptake in the granulocyte population was used as an internal standard. Thus, the ratio of DiOC6 uptake in CD34+ cells to DiOC6 uptake in granulocytes was evaluated before and 6 hours after TBI. The increase in the ratio accounts for a status of hyperpolarization of the mitochondrial membrane, which is considered to be an early marker of apoptosis. Study groups and treatments Mouse study. Twenty-four mice were randomly assigned to each group. Seven treatments were evaluated using S, F, T, 3, and SDF-1 alone or in combination: TPO, SDF-1, 3F (S + F + T), 4F (S + F + T + 3), and 5F (4F + SDF-1) were given 2 hours and 24 hours after TBI. Each cytokine was administered at 50 µg/kg for each administration. The last 2 treatments were 4Fsingle (4F given only at 2 hours after TBI, each cytokine given at 50 µg/kg) and 4F10 (4F given at 2 hours and 24 hours after TBI, each cytokine given at 10 µg/kg). Preliminary experiments showed that 4F induced a similarly protective effect by either the intravenous or the intraperitoneal route. Cytokine solutions were prepared extemporaneously with pyrogen-free sterile Dulbecco phosphate-buffered solution containing 0.5% human serum albumin and injected intraperitoneally in a volume of 200 ± 20 µL (according to the animal's weight) at 2 hours and 24 hours after irradiation. Four control groups that received cytokine diluent were evaluated throughout the study; 4F and 5F evaluation was carried out twice. Monkey study.
Six monkeys underwent 5 Gy Survival follow-up During the first 30 days, mice were observed daily to record survival. Weight and behavior were monitored. After 30 days, animals were observed 3 times a week. Autopsies were performed in long-term deceased animals. After 360 days, surviving mice were killed by cervical dislocation and were autopsied. Spleens and femurs were collected. Spleens were stained with formalin and weighed. BM was harvested, and total nucleated cell (TNC) counts were assessed, as were differential cell counts using cytospins (Shandon, Pittsburgh, PA) stained with May-Grünwald-Giemsa. BM clonogenicity (granulocyte macrophage-colony-forming unit [GM-CFU] and erythroid burst-forming unit [BFU-e]) was evaluated using a short-term methylcellulose assay (RTM Mabio). Briefly, 15 × 103/mL femoral BM TNCs were plated in triplicate in 6-well plates with recombinant murine SCF, FLT-3 ligand, IL-3, GM-CSF, and EPO (R&D Systems), and CFU scoring was performed at 10 days of culture.Statistics The mouse study was conducted over 4 experiments, and no significant difference in survival among the 4 control groups was observed ( 2 evaluation), allowing for a global
statistical comparison. Survival curves were compared using
Kaplan-Meier analysis, and statistical significance was determined
between groups using 2 analysis with Yates correction.
Spleen weights, BM TNC, and clonogenicity were compared using the
Mann-Whitney U test. The latter test was also used to
analyze the effect of 4F on the cell cycle distribution of baboon
BM-irradiated CD34+ cells versus unirradiated cells.
Short- term survival The onset of lethality was delayed by 3 days in mice treated with 5F in comparison with the other 2 treatments and with the control group (11.5 days instead of 8 days). Thirty-day survival rates are presented in Figure 1A and Table 1. The average survival rate of controls was 8.3%. All treated groups displayed 30-day survival rates significantly higher than those of the control group. Multiple cytokine treatments proved to be more efficient than single therapy. In fact, 5F and 4F afforded the best protection (survival rates, 87.5% and 81.25%, respectively) when given at 50 µg/kg 2 hours and 24 hours after TBI. Neither was statistically different from the other (P = .36). Both treatments were more efficient than TPO (58.3%), 3F (50%), 4F10 (45.8%), and SDF-1 (29.2%), as shown in Table 2, and 5F was better than 4Fsingle (62.5%). The benefit conferred by 2 injections of 4F rather than a single injection was not significant. Thus, the combination of cytokines administered appears crucial for efficacy.
In vitro effect of 4F on irradiated HSPC cell cycle distribution Freshly isolated baboon-mobilized PB CD34+ cells are mainly in the G0/G1 phases of the cell cycle, with only a reduced subset in the S and G2M phases (67.8% ± 5.8%, 29.9% ± 4.8%, and 2.4% ± 1.2%, respectively), as shown in Table 3 and Figure 2. Unirradiated (unir) CD34+ cells incubated for 24 hours in serum-free medium in the presence of 4F exhibited an important reduction of G0 cell subset and an increase of G1 and S/G2/M cell subsets (40.2% ± 12.6%, 39.5% ± 6%, 19.8% ± 7.6%, respectively; P < .05 for G0, G1, and S/G2/M) (day 1 unir vs day 0). In contrast to unirradiated cells, in vitro-irradiated cells incubated with 4F for 24 hours showed the maintenance of their initial cell cycle distribution (P > .05 for G0 and S/G2/M, day 0 vs day 1, 2.5 Gy) (P < .05 for G0, G1, and S/G2/M, day 1 unir vs day1, 2.5 Gy). From day 3 of culture with 4F, irradiated CD34+ cells were stimulated to cycle as did unirradiated cells. At 3 days, the relative cell cycle distributions were similar even though, in terms of absolute cell number, unirradiated cells exhibited a greater expansion rate (K4F = 2.6 ± 0.7) than irradiated cells (K4Firrad = 0.55 ± 0.34). At 7 days, the respective cell amplification rates were K4F = 12.5 ± 0.7 and K4Firrad = 2.9 ± 0.6.
4F administration leads to a reduction of in vivo RI apoptosis at the HSPC level Monkey BM CD34+ cells harvested 6 hours after 5 Gy TBI exhibited a notable increase in mitochondrial transmembrane potential compared with their own initial value (Figure 3). In contrast, this hyperpolarization did not occur in animals given 4F 2 hours after TBI.
Long-term survival Data regarding 300-day survival are presented in Figure 1B and Table 1. Delayed death occurred in all treated groups and in the few surviving controls, mainly from day 150 after TBI, well beyond the classical period of RI hematologic death. In contrast, age-matched unirradiated control (UC) animals experienced no deaths in 360 days of follow-up. Despite delayed death in irradiated animals, all treatments except 4F10 and SDF-1 induced significantly improved long-term survival rates. Multiple cytokine combinations remained the most effective treatments, resulting in survival rates of 43.8% (5F), 50% (4F), and 41.7% (4Fsingle) versus 29.2% (TPO), 12.5% (SDF-1), and 3.3% (control). Moreover, 4F injected only 2 hours after TBI at 50 µg/kg (4Fsingle) resulted in greater long-term survival (41.7%) than when injected 2 hours and 24 hours after TBI at 10 µg/kg (4F10, 8.3%), in accordance with short-term results. The benefit conferred by 5F and 4F versus TPO was not significant.Autopsies carried out on animals that died between 30 days and 300 days
after TBI showed a pattern of cachexia and multiorgan failure.
Autopsies performed at 360 days in long-term survivors revealed signs
of macroscopic anemia associated with liver disease in most animals and
4 cases of cancer (1 myosarcoma, 2 thymomas, 1 leukemia) in different
groups. Spleens and femurs from mice of groups 5F, 4F, TPO, SDF-1, and
UC were collected at that time. Spleen weights are reported in Table
4. In contrast to the spleens of groups
4F and TPO, those of group 5F were significantly smaller than UC
spleens. BM TNC counts (Tables 4 and 5)
decreased in all treated groups to values equal to 64.5% (5F), 77.4%
(4F), 76.3% (TPO), and 61.5% (SDF-1) of the UC level. However, this reduction in BM TNC was not significant for 5F (P = .06 vs
UC). The most striking unexpected observation was that all treated animals proved to be significantly depleted of BM colony-forming units
(CFUs) in comparison with UC. BM CFU of treated groups were 27.8%
(5F), 56.1% (4F), 59.1% (TPO), and 44.1% (SDF-1) of UC CFU. In fact,
though group 5F appeared significantly more depleted of CFU than other
treated groups (Table 5), BM megakaryocytic progenitors were twice as
numerous in group 5F as in other groups, UC included (4.1% of TNC vs
2% on average; P < .01). At 360 days, there was only one
surviving irradiated control mouse whose BM displayed a marked
reduction in TNC and clonogenicity (Table 4).
The results of this study support the concept that cytokine cooperation is important for hematopoietic recovery from radiation injury. They also suggest that short-term treatment is efficient. This work not only accounts for the short-term hematopoietic activity of cytokines on the irradiated organism, it also accounts for the long-term response to cytokine treatment. To date the prolonged administration of GM-CSF or G-CSF remains the criterion standard of cytokine therapy for irradiated victims in spite of their granulocyte-restricted activity.7,26 In most preclinical trials, HGF administration starts from the day after myeloablative injury, and the duration of treatment covers 15 to 21 days until neutrophil or platelet recovery.2-6,27 Few combinations have been used despite promising studies in myeloablated nonhuman primates that entailed 2 cytokines4-6 or synthetic dual cytokine receptor agonists.3,27 Thus far, nuclear accident victims have been treated with GM-CSF and IL-328 or G-CSF + GM-CSF.7 More recently, the victims of the criticality accident in Tokai-mura were given G-CSF, MGDF, and erythropoietin in combination.8 However, in these dramatic situations, cytokine therapy was initiated after a variable delay following radiation exposure, which might have reduced its efficacy. Furthermore, the prolonged administration of HGF may induce notable proinflammatory29 or immunogenic activity.3,9 The potential therapeutic benefit of early and short-term administration of antiapoptotic cytokines has been suggested by some authors whose studies have been primarily focused on TPO.12,15 For some years the latter has emerged as a key factor, not only for its thrombopoietic activity but also as a survival factor on the HSPC.30 TPO/MGDF counteracts lethal myelosuppression when given early after radiobiologic or radiocombined damage.12,15,31-33 Moreover, this beneficial effect can be obtained with a single administration,12,15,31-34 which is as effective as 7 repeated injections for hematopoietic recovery and prevention of death.32 The single administration of TPO to humans has been reported to maintain hematopoiesis without inducing adverse effects.35 As demonstrated by Pestina et al,15 the survival effect involves the mitigation of the p53 apoptotic pathway, but TPO/Mpl-ligand appears to act downstream of p53. IL-1 and tumor necrosis factor (TNF) also exhibit radioprotective
effects, but these cytokines have been discarded because of high
toxicity.36 In fact, given that hematopoiesis is regulated by a subtle balance between numerous positive and negative regulators whose cooperation is required to optimize cell survival, proliferation, and differentiation, we chose to evaluate in vivo the therapeutic efficacy of combinations of 5 different cytokines In the present study, we first focused on RI short-term hematopoietic
cell death evaluated by the classical 30-day survival end-point. We
have based our 2 injection treatments on the in vitro capacity of SFT3
to exert a strong antiapoptotic effect when added early to HSPC and to
initiate the production of radioprotective progenitors. The cytokine
dose (50 µg/kg for each cytokine of the combination) was chosen in
accordance with our in vitro study, which demonstrated the necessity
for using high concentrations to counteract RI apoptosis (ie, 50 ng/mL
is better than 10 ng/mL for each cytokine of the
combination),1 and the Pestina et al15 study,
in which a dose range of 50 to 65 µg/kg was selected to reduce in
vivo RI apoptosis. Here we show that administering the SFT3 combination
at 50 µg/kg (each cytokine), supplemented or not with SDF-1 To confirm that 4F efficacy was related at least partially to apoptosis reduction at the HSPC level, we used a monkey model of 5 Gy TBI. BM CD34+ cells were harvested 6 hours after irradiation, and we looked for mitochondrial membrane hyperpolarization as an early marker of active cell death.25 We brought evidence that 4F preserved CD34+ cells in vivo from RI apoptosis because no hyperpolarization occurred. On the contrary, BM CD34+ cells from untreated irradiated animals exhibited significant hyperpolarization in comparison with the preirradiation value, accounting for the initial phase of apoptosis. These data and those on the cell cycle sustain the hypothesis that the predominant effect of 4F treatment during the first 24 hours after irradiation consists of apoptosis reduction rather than cell proliferation. The benefit provided to mice by SFT3 was also demonstrated in comparison with TPO-treated mice, which argues in favor of an additive or synergistic effect of the combination. In fact, TPO-treated mice in our model exhibited a survival rate consistent with that shown by Mouthon et al,12,32 who administered TPO 2 hours after TBI. By contrast, Pestina et al15 and Abushullaih et al33 obtained a higher survival rate by giving TPO immediately after lethal myelosuppression, which is unfortunately incompatible with the medical management of accidentally irradiated victims.15,33 Yet, their result is in agreement with the benefit that should be expected from the early counteraction of apoptosis. Preliminary data with the 4F combination in irradiated monkeys suggest that SFT3 can sustain multilineage recovery, including lymphopoiesis (F.H., M.D., manuscript in preparation). In the study by Neelis et al,31 single administration 2 hours after TBI proved to be significantly more efficient than treatment at 24 hours; therefore, we evaluated the efficacy of SFT3 given only at 2 hours after TBI. The benefit conferred by 2 injections of 4F versus a single injection was not actually significant. Interestingly, the dose administered appeared crucial, as did the multiple cytokine composition of the combination. In our model, dose reduction of SFT3 to 10 µg/kg or IL-3 withdrawal (2-hour and 24-hour schedules) only allowed for reduced survival rates. Finally, SDF-1 alone was less efficient than TPO, but recent studies suggest that SDF-1 bioavailability has to be improved before development for clinical use.39 In this study we then focused on long-term follow-up to assess whether the cytokines selected and their combinations could behave as long-term protectors. In fact, if numerous studies conducted in mice have accounted for long-term follow-up,40-43 data on the effects in aging irradiated animals of early cytokine administration are lacking. In our study, delayed death mainly observed from day 150 after TBI was likely to occur from hematologic failure (hematopoietic and thrombotic disorders) and nonhematopoietic defects (fibrosis-associated multiorgan failure). In the Barnes et al42 study, most late deaths of untreated irradiated mice occurred between 9 and 32 weeks after mid-lethal X-irradiation (earlier than in our treated irradiated mice), and the most frequent syndromes observed were liver necrosis, diarrhea, pleural effusion, and aplastic anemia. In our study, no predominant etiology for death was observed. In particular, oncogenesis, which could be expected to be highly increased after antiapoptotic treatment, affected only a minority of long-term survivors, at least from a macroscopic analysis. From a clinical point of view, these survivors were comparable to healthy animals regarding body weight, food intake, and locomotion. However, when compared with UC, hematopoiesis was impaired in most of the treated animals, as shown by the reduction in BM TNC and clonogenic cell counts. This impairment was observed for all treated groups but appeared greater for 5F than for TPO, 4F, and SDF-1. These results are consistent with lasting impairment of marrow stem and progenitor cell compartments previously reported in various species following irradiation.40,41,43,44 BM CFU depletion could be explained by 3 mechanisms: (1) RI apoptosis,
because our in vitro results showing that SFT3 protects approximately
12.3% of CD34+ cells irradiated at 4 Gy from
apoptosis13 support the hypothesis that such cytokine
combinations prevent apoptosis only partially in vivo; (2) partial stem
cell exhaustion following cytokine-induced overstimulation.31 In fact, whole-body survival provided
by multiple cytokines involves the production of short-term
radioprotective progenitors that occurs, in the range of lethal
radiation doses, at the expense of long-term stem and progenitor cells.
As proof of the contribution of radioprotective progenitors, we clearly observed 2 striking waves of platelet production 8 and 23 days later,
issued respectively from megakaryocytes and megakaryoblasts in 5 Gy
A crucial issue is the selection of the ideal treatment for patients who have sustained severe radiobiologic injury. In our study, the short-term injection of multiple cytokine combinations was well tolerated and proved to be more efficient than single factors in promoting short-term survival in mice. It is possible that the administration of factors such as protease inhibitors, p53 chemical inhibitors,46 and negative regulators of hematopoiesis, with or without sequential cytokines such as antiapoptotic factors followed by colony-stimulating factors, may result in improved long-term hematopoiesis.
We thank S. Doulay, C. Dupuy, N. Grenier, V. Leroux, and L. Crépin for their technical assistance.
Submitted June 3, 2002; accepted November 22, 2002.
Prepublished online as Blood First Edition Paper, December 5, 2002; DOI 10.1182/blood-2002-06-1634.
Supported by a grant from Electricité de France.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Francis Hérodin, Centre de Recherches du Service de Santé des Armées, Departement of Radiobiology, Radiohematology Unit 24, avenue des Maquis du Grésivaudan 38702, La Tronche Cedex France; e-mail: francis.herodin{at}wanadoo.fr.
1. Monroy RL. Radiation effects on the lymphohematopoietic system: a compromise in immune competency. In: Conklin JJ,Walker RI, eds. Military Radiobiology. Orlando, FL: Academic Press; 1987:111-134. 2. Thierry D, Gourmelon P, Parmentier C, Nenot JC. Hematopoietic growth factors in the treatment of therapeutic and accidental irradiation induced bone marrow aplasia. Int J Radiat Biol. 1995;67:103-117[Medline] [Order article via Infotrieve]. 3. MacVittie TJ, Farese AM. Cytokine-based treatment for acute radiation-induced myelosuppression: preclinical and clinical perspective. In: Ricks RC,Berger ME,O'Hara FM Jr, eds. The Medical Basis for Radiation Accident Preparedness. New York, NY: Parthenon Publishing Group; 2002:53-72.
4.
Farese AM, Williams DE, Seiler FR, MacVittie TJ.
Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage-colony-stimulating factor in a primate model of radiation-induced marrow aplasia.
Blood.
1993;82:3012-3018 5. Farese AM, Hunt P, Grab LB, MacVittie TJ. Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia. J Clin Invest. 1996;97:2145-2151[Medline] [Order article via Infotrieve]. 6. Neelis KJ, Dubbelman YD, Qingliang L, Thomas R, Eaton DL, Wagemaker G. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp Hematol. 1997;25:1084-1093[Medline] [Order article via Infotrieve]. 7. Jinaratana V. The radiological accident in Thailand. In: Ricks RC,Berger ME,O'Hara FM Jr, eds. The Medical Basis for Radiation Accident Preparedness. New York, NY: Parthenon Publishing Group; 2002:283-301. 8. Maekawa K. Overview of medical care for highly exposed victims in the Tokai Mura accident. In: Ricks RC,Berger ME,O'Hara FM Jr, eds. The Medical Basis for Radiation Accident Preparedness. New York, NY: Parthenon Publishing Group; 2002:313-318. 9. Li J, Xia Y, Bertino A, Coburn J, Kuter DJ. Characterization of an anti-thrombopoietin antibody that developing a cancer patient following the injection of Peg-rhuMGDF [abstract]. Blood. 1999;94:51.
10.
Neta R, Oppenheim JJ.
Cytokines in therapy of radiation injury.
Blood.
1988;72:1093-1095 11. Sureda A, Valls A, Kadar E, et al. A single dose of G-CSF modifies radiation-induced death in B6D2F1 mice. Exp Hematol. 1993;21:1605-1607[Medline] [Order article via Infotrieve]. 12. Mouthon MA, Gaugler MH, Van der Meeren A, Vandamme M, Gourmelon P, Wagemaker G. Single administration of thrombopoietin to lethally irradiated mice prevents infectious and thrombotic events leading to mortality. Exp Hematol. 2001;29:30-40[CrossRef][Medline] [Order article via Infotrieve].
13.
Drouet M, Mathieu J, Grenier N, Multon E, Sotto JJ, Hérodin F.
The reduction of in vitro radiation-induced Fas-related apoptosis in CD34+ progenitor cells by SCF, Flt-3 ligand, TPO and IL-3 in combination resulted in CD34+ cell proliferation and differentiation.
Stem Cells.
1999;17:273-285
14.
Domen J, Gandy KL, Weissman IL.
Systemic overexpression of Bcl-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation.
Blood.
1998;91:2272-2282
15.
Pestina TI, Cleveland JL, Yang C, Zambetti GP, Jackson CW.
MPL-ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis.
Blood.
2001;98:2084-2090 16. Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol. 2002;30:513-528[CrossRef][Medline] [Order article via Infotrieve]. 17. Van Bekkum DW. Radiation sensitivity of the hematopoietic stem cell. Radiat Res. 1991;128:S4-S8[CrossRef][Medline] [Order article via Infotrieve].
18.
Lataillade JJ, Clay D, Dupuy C, et al.
Chemokine SDF-1 enhances circulating CD34+ cell proliferation in synergy with cytokines: possible role in progenitor survival.
Blood.
2000;95:756-768
19.
Lataillade JJ, Clay D, Bourin P, et al.
SDF-1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G0/G1 transition in cells: evidence for an autocrine/paracrine mechanism.
Blood.
2002;99:1117-1129 20. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331-1339[Medline] [Order article via Infotrieve]. 21. FitzGerald TJ, McKenna M, Rothstein L, Daugherty C, Kase K, Greenberger JS. Radiosensitivity of human bone marrow granulocyte-macrophage progenitor cells and stromal colony-forming cells: effect of dose rate. Radiat Res. 1986;107:205-215[CrossRef][Medline] [Order article via Infotrieve]. 22. Norol F, Drouet M, Pflumio F, et al. Ex vivo expansion marginally amplifies repopulating cells from baboon peripheral blood mobilized CD34+ cells. Br J Haematol. 2002;117:924-934[CrossRef][Medline] [Order article via Infotrieve]. 23. Jordan CT, Yamasaki G, Minamoto D. High-resolution cell cycle analysis of defined phenotypic subsets within primitive human hematopoietic cell populations. Exp Hematol. 1996;24:1347-1355[Medline] [Order article via Infotrieve]. 24. Hertveldt K, Philippé J, Thierens J, et al. Flow cytometry as a quantitative and sensitive method to evaluate low dose radiation induced apoptosis in vitro in human peripheral blood lymphocytes. Int J Radiat Biol. 1997;71:429-433[CrossRef][Medline] [Order article via Infotrieve]. 25. Scarlett JL, Sheard PW, Hughes G, et al. Changes in mitochondrial membrane potential during stauroporine induced apoptosis in Jurkat cells. FEBS Lett. 2000;475:267-272[CrossRef][Medline] [Order article via Infotrieve]. 26. Gale RP, Butturini A. Use of hematopoietic growth factors in radiation accidents. Int J Radiat Oncol Biol Phys. 1990;19:1291-1295[Medline] [Order article via Infotrieve].
27.
Farese AM, Smith WG, Giri JG, Siegel N, McKearn JP, MacVittie TJ.
Promegapoeitin 1A, an engineered chimeric IL-3 and MPL receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedule following radiation-induced myelosuppression in nonhuman primates.
Stem Cells.
2001;19:329-338
28.
Baranov AE, Selidovkin GD, Butturini A, Gale RP.
Hematopoietic recovery after 10 Gy acute total body irradiation.
Blood.
1994;83:596-599 29. Negrin RS. Clinical applications of hematopoietic growth factors. In: Thomson AW, ed. The Cytokine Handbook. San Diego, CA: Academic Press; 1998:803-822.
30.
Borge OJ, Ramsfjell V, Cui L, et al.
Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38
31.
Neelis KJ, Visser TP, Dimjati W, et al.
A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short term multilineage spleen repopulating cells at the transient expense of bone marrow repopulating cells.
Blood.
1998;92:1586-1597 32. Mouthon MA, Van der Meeren A, Gaugler MH, et al. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. Int J Radiat Oncol Biol Phys. 1999;43:867-875[CrossRef][Medline] [Order article via Infotrieve]. 33. Abushullaih BA, Pestina TI, Srivastava DK, Jackson CW, Daw NC. A schedule of recombinant MPL ligand highly effective at preventing lethal myelosuppresion in mice given carboplatin and radiation. Exp Hematol. 2001;29:1425-1431[CrossRef][Medline] [Order article via Infotrieve]. 34. Ulich TR, del Castillo J, Senaldi G, et al. The prolonged hematologic effects of a single injection of PEG-rhuMGDF in normal and thrombocytopenic mice. Exp Hematol. 1999;27:117-130[CrossRef][Medline] [Order article via Infotrieve].
35.
Kuter DJ, Goodnough LT, Romo J, et al.
Thrombopoietin therapy increases platelet yields in healthy platelet donors.
Blood.
2001;98:1339-1345 36. Dinarello CA. Interleukin-1. In: Thomson AW, ed. The Cytokine Handbook. San Diego, CA: Academic Press; 1998:35-72.
37.
Fukuda S, Foster RG, Porter SB, Pelus LM.
The antiapoptotic protein survivin is associated with cell cycle entry of normal cord blood CD34+ cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells.
Blood.
2002;100:2463-2471
38.
Fukuda S, Pelus LM.
Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis.
Blood.
2001;98:2091-2100 39. Perez L, Alpdogan O, Shieh J, et al. In vivo effects of stromal derived factor 1 (SDF-1/CXCL12) on human megakaryocytopoiesis and mobilization of human hematopoietic progenitors [abstract]. Blood. 2001;98:799. 40. Croizat H, Frindel E, Tubiana M. Long-term radiation effects on the bone marrow stem cells of C3H mice. Int J Radiat Biol. 1979;36:91-99. 41. Wangenheim KH, Peterson HP, Hubner GE, Feinendegen LE. Long-term residual radiation effect in the murine hematopoietic stem cell compartment. Ann N Y Acad Sci. 1985;459:221-231[Medline] [Order article via Infotrieve]. 42. Barnes DWH, Bungay GT, Mole RH. Delayed mortality after mid-lethal exposure to whole body irradiation and its modification by treatment with syngenic lymph node or bone marrow cells. Int J Rad Biol. 1966;11:409-427. 43. Knospe WH. Long-term bone marrow damage after irradiation. In: Testa NG,Gale RP, eds. Hematopoiesis: long-term effects of chemotherapy and radiation. New York, NY: Marcel Dekker; 1988:93-130. 44. Nothdurft W, Steinbach KH, Fliedner TN. Dose- and time-related quantitative and qualitative alterations in the granulocyte/macrophage progenitor cell (GM-CFC) compartment of dogs after total body irradiation. Radiat Res. 1984;98:332-344[CrossRef][Medline] [Order article via Infotrieve]. 45. Cronkite EP, Inoue T, Hirabayashi Y. Are stem cells exposed to ionizing radiation in vivo as effective as nonirradiated transfused stem cells in restoring hematopoiesis? Exp Hematol. 1993;21:823-825[Medline] [Order article via Infotrieve].
46.
Komarov PG, Komarova EA, Kondratov RV, et al.
A chemical inhibitor of p53 that protects mice from side effects of cancer therapy.
Science.
1999;285:1733-1737
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  T. Zhao, D. Zhang, R. W. Millard, M. Ashraf, and Y. Wang Stem cell homing and angiomyogenesis in transplanted hearts are enhanced by combined intramyocardial SDF-1{alpha} delivery and endogenous cytokine signaling Am J Physiol Heart Circ Physiol, April 1, 2009; 296(4): H976 - H986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Matsumura-Takeda, S. Sogo, Y. Isakari, Y. Harada, K. Nishioka, T. Kawakami, T. Ono, and T. Taki CD41+/CD45+ Cells Without Acetylcholinesterase Activity Are Immature and a Major Megakaryocytic Population in Murine Bone Marrow Stem Cells, April 1, 2007; 25(4): 862 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Chute, G. G. Muramoto, A. B. Salter, S. K. Meadows, D. W. Rickman, B. Chen, H. A. Himburg, and N. J. Chao Transplantation of vascular endothelial cells mediates the hematopoietic recovery and survival of lethally irradiated mice Blood, March 15, 2007; 109(6): 2365 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Ohab, S. Fleming, A. Blesch, and S. T. Carmichael A Neurovascular Niche for Neurogenesis after Stroke J. Neurosci., December 13, 2006; 26(50): 13007 - 13016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kortesidis, A. Zannettino, S. Isenmann, S. Shi, T. Lapidot, and S. Gronthos Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells Blood, May 15, 2005; 105(10): 3793 - 3801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Charrier, A. Michaud, S. Badaoui, S. Giroux, E. Ezan, F. Sainteny, P. Corvol, and W. Vainchenker Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells Blood, August 15, 2004; 104(4): 978 - 985. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Drouet, F. Mourcin, N. Grenier, V. Leroux, J. Denis, J.-F. Mayol, P. Thullier, J.-J. Lataillade, and F. Herodin Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis Blood, February 1, 2004; 103(3): 878 - 885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dainiak, J. K. Waselenko, J. O. Armitage, T. J. MacVittie, and A. M. Farese The Hematologist and Radiation Casualties Hematology, January 1, 2003; 2003(1): 473 - 496. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
-irradiation promotes survival
Top
Abstract
Introduction
SCF, FLT-3 ligand, TPO, IL-3, and SDF-1
bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin.
Blood.
1997;90:2282-2292